LABCORP HOLDINGS INC. 8-K filed 2026-09-10

Labcorp Holdings Inc. filed a Form 8-K on 2026-09-10 under Item 7.01, Regulation FD Disclosure, in connection with its 2026 Investor Day. The company, which trades on the NYSE under the ticker LH and is classified under SIC 8071, Services-Medical Laboratories, is a large accelerated filer based at 358 S MAIN ST, BURLINGTON, NC, 27215. It has previously filed under the names LABORATORY CORP OF AMERICA HOLDINGS and NATIONAL HEALTH LABORATORIES HOLDINGS INC. Two exhibits are furnished: a press release dated September 10, 2026 as Exhibit 99.1, and the Investor Day presentation dated September 10, 2026 as Exhibit 99.2, also posted on the investor relations website. The substance for an analyst is the long-term outlook. Labcorp reaffirmed its full-year 2026 guidance, which it says was last updated on July 30, 2026 and which assumes foreign exchange rates effective as of June 30, 2026. Through 2029 it expects compound annual revenue growth between 5% and 8%, adjusted operating margin expansion between 75 and 150 basis points by the end of 2029, compound annual adjusted EPS growth between 8.5% and 11.5%, and compound annual free cash flow growth in line with adjusted earnings growth. Chairman and CEO Adam Schechter tied that outlook to an expectation of above-market performance. CFO Julia Wang attributed confidence in it to what she called a disciplined value creation framework. The company named four strategic priorities behind the numbers: leading in specialty testing through innovation in oncology, neurology, autoimmune diseases and women's health; being a partner of choice for health systems and pharmaceutical companies; driving personalized health solutions; and using advanced technology including artificial intelligence and robotics. One procedural point matters. The filing states the information and exhibits are not deemed filed for purposes of Section 18 of the Exchange Act and are not incorporated by reference except by express reference. Furnished material carries different liability treatment from filed material. The excerpt available here stops at the start of the 2026 guidance table, so the specific guidance figures are not in the record. The report was signed by Kathryn W. Kyle, Executive Vice President, Chief Legal Officer and Corporate Secretary.